IGF-1 LR3
1mg
IGF-1 LR3 is a synthetic analogue of insulin-like growth factor-1 (IGF-1) that has attracted research interest for its prolonged biological activity and role in cellular growth, metabolism, and tissue physiology. Supplied as a high-purity lyophilised peptide for laboratory research purposes only.
$147.00
Add to wishlist Add to compareAsk about productDescription
IGF-1 LR3 (Long Arg3 Insulin-Like Growth Factor-1) is a modified analogue of naturally occurring insulin-like growth factor-1 (IGF-1). Through the substitution of arginine at position 3 and the addition of a 13-amino acid extension at the N-terminus, IGF-1 LR3 exhibits a significantly longer half-life and reduced binding to insulin-like growth factor binding proteins (IGFBPs) compared with native IGF-1.
Researchers have investigated IGF-1 LR3 for its role in cellular proliferation, protein synthesis, skeletal muscle physiology, tissue regeneration, and metabolic regulation. Its prolonged biological activity has made it a valuable research tool for studying IGF-1 signalling pathways and growth factor biology across a range of experimental models.
Areas of Scientific Interest
- Research has investigated IGF-1 LR3 for its prolonged activation of insulin-like growth factor-1 receptors and downstream cellular signalling pathways.
- Experimental studies have explored its role in cellular growth, protein synthesis, skeletal muscle physiology, and tissue regeneration.
- Researchers have examined IGF-1 LR3 in studies involving metabolism, nutrient utilisation, and endocrine regulation.
- Ongoing investigations continue to evaluate the biological effects of prolonged IGF-1 signalling in regenerative medicine, exercise physiology, and age-related research.
Product Features
- High-purity lyophilised peptide
- Contains 1mg IGF-1 LR3
- Manufactured for laboratory and scientific research
- Quality tested for identity and purity
- Securely packaged to help maintain product integrity
References
- Francis GL, et al. Novel recombinant fusion protein analogues of insulin-like growth factor-I with enhanced biological potency. Journal of Molecular Endocrinology.
- Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The Somatomedin Hypothesis: 2001. Endocrine Reviews.
- Jones JI, Clemmons DR. Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions. Endocrine Reviews.
Reviews
There are no reviews yet.